Every 10-Q that Alector, Inc. (ALEC) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ALEC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ALEC filings page.
Alector, Inc. reported Q2 2026 results showing collaboration revenue of $3.3 million, down from $7.9 million a year earlier, and a net loss of $23.0 million versus $30.5 million. For the first six months, the net loss was $45.9 million compared with $71.0 million in 2025.
Cash, cash equivalents, and marketable securities totaled $172.8 million as of June 30, 2026, and the company states this provides runway at least through 2027. Total liabilities were $212.8 million and stockholders’ equity was a deficit of $10.0 million, with deferred revenue of $162.9 million from its GSK collaboration.
GSK discontinued nivisnebart and latozinemab after unfavorable analyses and gave notice on July 6, 2026 to terminate the collaboration effective January 2, 2027. Alector is refocusing on its wholly owned ABC platform programs, including AL137 for Alzheimer’s disease, tau siRNA program AL064/AL164, and AL050 for Parkinson’s disease.
Alector, Inc. reported a Q1 2026 net loss of $22.9 million, an improvement from $40.5 million a year earlier as it sharply reduced operating expenses. Collaboration revenue from its GSK partnership declined to $1.0 million from $3.7 million, mainly due to lower manufacturing activity.
Research and development expense fell to $17.9 million and general and administrative expense to $8.1 million, reflecting 2025 workforce reductions and program wind-downs. Cash, cash equivalents, and marketable securities totaled $206.5 million, which the company believes will fund operations at least through 2027.
Alector is pivoting toward its ABC blood–brain barrier platform, advancing preclinical programs such as AL037/AL137 for Alzheimer’s disease, AL050 for Parkinson’s and Lewy body dementia, and an siRNA pipeline. In April 2026, GSK discontinued the Phase 2 PROGRESS-AD trial of nivisnebart after a futility analysis.
Alector (ALEC) filed its Q3 2025 10‑Q, reporting collaboration revenue of $3.3 million and a net loss of $34.7 million. Operating expenses fell to $40.9 million on lower R&D and G&A. Cash, cash equivalents, and marketable securities totaled $291.1 million as of September 30, 2025, and management states this provides runway into 2027.
The company announced topline Phase 3 INFRONT‑3 results: latozinemab did not meet the clinical co‑primary endpoint in FTD‑GRN; the open‑label extension and continuation study will be discontinued. On October 21, 2025, Alector committed to a 47% workforce reduction with expected restructuring charges of $7.5 million. The GSK collaboration remains central, with deferred revenue of $179.0 million and current refund liability of $21.8 million. Nivisnebart Phase 2 in early Alzheimer’s completed enrollment; trial completion is expected in 2026 with an independent interim analysis planned in the first half of 2026.
Shares outstanding were 109,151,472 as of October 31, 2025. Year‑to‑date ATM sales delivered $14.7 million net proceeds through September, with an additional $5.3 million in October.